(Q36094452)

12 August 2017

1 reference

title

Management of hepatitis C virus in special populations: patient and treatment considerations (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Nezam H Afdhal

2

0 references

Robert Gish

object named as

Robert G Gish

series ordinal

1

0 references

K. Rajender Reddy

series ordinal

4

object named as

K Rajender Reddy

1 reference

12 August 2017

Douglas T Dieterich

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Clinical Gastroenterology and Hepatology

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

311-318

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Natural history of hepatitis C: its impact on clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Prevention and treatment of hepatitis C in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Risk factors for hepatitis C virus infection among homeless adults

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hematologic disorders associated with hepatitis C virus infection and their management

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Outcomes of acute rejection after interferon therapy in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C virus infection: co-infection with HIV and HBV

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treating hepatitis C in methadone maintenance patients: an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treatment of hepatitis C infection in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C and the correctional population

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treatment of chronic hepatitis C in a state correctional facility

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Adopting more systematic approaches to hepatitis C treatment in correctional facilities

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Epidemiology of hepatitis C virus infection in American veterans

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Prevalence of Hepatitis C virus infection in a sample of homeless veterans

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Spectrum of disease in U.S. veteran patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Hepatitis C in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Management of interferon therapy nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Treatment of chronic hepatitis C in nonresponders to previous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900666-4

7 January 2021

10.1016/S1542-3565(04)00666-4

Identifiers

DOI

1 reference

12 August 2017

1 reference